Your browser doesn't support javascript.
loading
Medical, surgical, and physical treatments for Parkinson's disease.
Foltynie, Tom; Bruno, Veronica; Fox, Susan; Kühn, Andrea A; Lindop, Fiona; Lees, Andrew J.
Afiliação
  • Foltynie T; Department of Clinical and Movement Neurosciences, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK. Electronic address: t.foltynie@ucl.ac.uk.
  • Bruno V; Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
  • Fox S; Edmond J Safra Program in Parkinson Disease, Krembil Brain Institute, Toronto Western Hospital, Toronto, ON, Canada; Division of Neurology, University of Toronto, Toronto, ON, Canada.
  • Kühn AA; Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Berlin, Germany; NeuroCure Cluster of Excellence, Charité-Universitätsmedizin Berlin, Berlin, Germany; Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Lindop F; University Hospitals of Derby and Burton NHS Foundation Trust, Specialist Rehabilitation, Florence Nightingale Community Hospital, Derby, UK.
  • Lees AJ; Department of Clinical and Movement Neurosciences, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK; Reta Lila Weston Institute of Neurological Studies, University College London, London, UK.
Lancet ; 403(10423): 305-324, 2024 Jan 20.
Article em En | MEDLINE | ID: mdl-38245250
ABSTRACT
Although dopamine replacement therapy remains a core component of Parkinson's disease treatment, the onset of motor fluctuations and dyskinetic movements might require a range of medical and surgical approaches from a multidisciplinary team, and important new approaches in the delivery of dopamine replacement are becoming available. The more challenging, wide range of non-motor symptoms can also have a major impact on the quality of life of a patient with Parkinson's disease, and requires careful multidisciplinary management using evidence-based knowledge, as well as appropriately tailored strategies according to the individual patient's needs. Disease-modifying therapies are urgently needed to prevent the development of the most disabling refractory symptoms, including gait and balance difficulties, cognitive impairment and dementia, and speech and swallowing impairments. In the third paper in this Series, we present the latest evidence supporting the optimal treatment of Parkinson's disease, and describe an expert approach to many aspects of treatment choice where an evidence base is insufficient.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Disfunção Cognitiva Limite: Humans Idioma: En Revista: Lancet Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Disfunção Cognitiva Limite: Humans Idioma: En Revista: Lancet Ano de publicação: 2024 Tipo de documento: Article